Your browser doesn't support javascript.
loading
The Effect of Uremic Solutes on the Organic Cation Transporter 2.
Cheung, Kit Wun Kathy; Hsueh, Chia-Hsiang; Zhao, Ping; Meyer, Timothy W; Zhang, Lei; Huang, Shiew-Mei; Giacomini, Kathleen M.
Afiliación
  • Cheung KWK; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California 94158; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation & Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20993.
  • Hsueh CH; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California 94158; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation & Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20993.
  • Zhao P; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation & Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20993.
  • Meyer TW; Division of Nephrology, School of Medicine, Stanford University, Stanford, California 94305.
  • Zhang L; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation & Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20993.
  • Huang SM; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation & Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20993.
  • Giacomini KM; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California 94158. Electronic address: kathy.giacomini@ucsf.edu.
J Pharm Sci ; 106(9): 2551-2557, 2017 09.
Article en En | MEDLINE | ID: mdl-28483424
ABSTRACT
Chronic kidney disease (CKD) is characterized by the accumulation of uremic solutes; however, little is known about how these solutes affect drug absorption and disposition. The goal of this study is to evaluate the effect of uremic solutes on the organic cation transporter, OCT2, which plays a key role in the renal secretion of many basic drugs. As a second goal, we reviewed the literature to determine whether there was evidence for the effect of CKD on the renal secretion of basic drugs. We first screened 72 uremic solutes as inhibitors of [14C]-labeled metformin uptake by OCT2. Seven were identified as inhibitors and 3 of them were determined to be clinically relevant. Of the 7 solutes, dimethylamine, malondialdehyde, trimethylamine, homocysteine, indoxyl-ß-d-glucuronide, and glutathione disulfide were novel OCT2 inhibitors. For 6 drugs that are known OCT2 substrates, both secretory clearance and glomerular filtration rate declined in parallel with progression of CKD from stage 2 to 4, suggesting that selective effects of uremic solutes on net tubular secretion of organic cations do not occur. Further clinical studies are warranted with a broader range of OCT2 substrates to determine whether CKD may differentially affect tubular secretion of drugs especially in patients with advanced CKD.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Toxinas Biológicas / Insuficiencia Renal Crónica / Transportador 2 de Cátion Orgánico / Riñón Límite: Humans Idioma: En Revista: J Pharm Sci Año: 2017 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Toxinas Biológicas / Insuficiencia Renal Crónica / Transportador 2 de Cátion Orgánico / Riñón Límite: Humans Idioma: En Revista: J Pharm Sci Año: 2017 Tipo del documento: Article
...